期刊文献+

HPLC-DAD-MS鉴定注射用雷贝拉唑钠杂质及其特征谱研究 被引量:3

Study on the impurities in rabeprazole sodium for injection using HPLC-DAD-MS
下载PDF
导出
摘要 目的利用高效液相色谱-二极管阵列检测器-质谱联用方法对注射用雷贝拉唑钠中杂质成分进行分析和结构推断。方法采用CenturySIL C18 BDS色谱柱(250 mm×4.6 mm,5μm),以磷酸盐缓冲液(磷酸氢二钠1.119 g和磷酸二氢钠0.179 g水溶液)-乙腈(体积比60∶40)为流动相,检测波长286 nm,流速1.0 mL·min-1,柱温(35±0.15)℃,进样量10μL,检测雷贝拉唑钠及其杂质;通过DAD检测器和质谱,获得在线紫外光谱图和质谱数据。结果通过在线紫外光谱图和质谱结果推断出可能含有的杂质结构,并测定了主要杂质含量限度。结论高效液相色谱-二极管阵列检测器-质谱联用技术可用于注射用雷贝拉唑钠中杂质的定性推断和定量测定。 Objective To analyze and infer the impurities′ structures in rabeprazole sodium for injection by HPLC-DAD-MS.Methods The operation was carried out on a CenturySIL C18 BDS column(250 mm×4.6 mm,5 μm),with the mobile phase consisting of a mixture of phosphate buffer(disodium hydrogen phosphate 1.119 g and sodium dihydrogen phosphate 0.179 g)-acetonitrile(V∶ V=60∶ 40).The detection wavelength was set at 286 nm,the flow rate was 1.0 mL · min-1,the column temperature was(35±0.15)℃ and the injection volume was 10 μL,the rabeprazole sodium and its impurities were detected,the online UV spectrum and MS data were obtained by using DAD detector and MS.Results According to the results of online UV spectra and mass spectrometry,the feasible impurities′ structures were inferred and the limits of the main impurities were determined.Conclusions The method of HPLC-DAD-MS can be used to identify the impurities in rabeprazole sodium for injection.
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2011年第6期433-437,共5页 Journal of Shenyang Pharmaceutical University
关键词 雷贝拉唑钠 高效液相色谱-质谱 杂质 rabeprazole sodium HPLC-MS impurity
  • 相关文献

参考文献9

二级参考文献36

共引文献41

同被引文献18

  • 1Garcia CV, Nudelman NS, Steppe M, et al. Structural elucidation of rabeprazole sodium photodegradation products [J]. JPharm BiomedAnal, 2008, 46 (1) : 88-93.
  • 2Vasu Dev R, Sai Uday Kiran G, Venkata Subbaiah B, et al. Identification of degradation products in stressed tablets of rabeprazole sodium by HPLC-hyphenated techniques [J]. Magn Resort Chem, 2009, 47 (4) : 443-448.
  • 3Miura M, Tada H, Satoh S, et al. Determination of rabe- prazole enantiomers and their metabolites by high- performance liquid chromatography with solid-phase extraction [J]. JPharm BiomedAnal, 2006, 41 (2) : 565-570.
  • 4Reddy GM, Bhaskar BV, Reddy PP, et al. Identification and characterization of potential impurities of rabeprazole sodium [J]. JPharm BiomedAnal, 2007, 43 (4) : 1262-1269.
  • 5Reddy GM, Mukkanti K, Bhaskar BV, et al. Synthesis of metabolites and related substances of rabeprazole, an anti- ulcerative drug [J]. Synthetic Commun, 2009, 39: 278-290.
  • 6Rao PS, Ray UK, Gupta PB, et al. Identification, isolation and characterization of new impurity in rabeprazole sodium [J]. J Pharm BiomedAnal, 2010, 52 (4): 620-624.
  • 7Reddy GM, Bhaskar BV, Reddy PP, et al. Identification and characterization of potential impurities of rabeprazole sodium [J]. JPharm BiomedAnal, 2007, 43 (4) : 1262-1269.
  • 8Vasu Dev R, Sai Uday Kiran G, Venkata Subbaiah B, et al. Identification of degradation products in stressed tablets of rabeprazole sodium by HPLC-hyphenated techniques [J]. Magn Reson Chem, 2009, 47 (5) : 443-448.
  • 9Rao PS, Ray UK, Gupta PB, et al. Identification, isolation and characterization of new impurity inrabeprazole sodium [J]. JPharm BiomedAnal, 2010, 52 (4): 620-624.
  • 10Garcia CV, Nudelman NS, Steppe M, et al. Structural elucidation of rabeprazole sodium photodegradation products [J]. JPharm BiomedAnal, 2008, 46 (1) : 88-93.

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部